Drug intelligence / Profile preview

9MW4113

Development stage: Phase 1
Lead developer: Mabwell
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

9MW4113 is a biosimilar candidate of dupilumab, a fully human monoclonal antibody developed by Mabwell (Shanghai) Bioscience. It targets the interleukin-4 receptor alpha (IL-4Rα) subunit, thereby inhibiting the signaling of both interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key drivers of Type 2 inflammation. The drug is being developed for the treatment of Th2-mediated inflammatory diseases, including atopic dermatitis and prurigo nodularis. Clinical development is currently in Phase 1, with studies comparing its pharmacokinetics, safety, and immunogenicity to the reference product, Dupixent.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on 9MW4113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9MW4113.

Explore the full profile